Improving R&D productivity of pharmaceutical companies through public–private partnership: Experiences from the Innovative Medicines Initiative

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 5, 2012, Pages 545-548

  Laverty, Hugh ^a   Gunn, Magda ^a   Goldman, Michel ^a  

^a Innovative Medicine Initiative   (Belgium)

Author keywords

drugs; pharmaceuticals; productivity; research and development

Indexed keywords

COOPERATION; DRUG DESIGN; DRUG INDUSTRY; EDITORIAL; EUROPEAN UNION; HUMAN; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; PUBLIC-PRIVATE PARTNERSHIP; RESEARCH;

COOPERATIVE BEHAVIOR; DRUG DESIGN; DRUG INDUSTRY; EFFICIENCY, ORGANIZATIONAL; EUROPEAN UNION; HUMANS; MODELS, ORGANIZATIONAL; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; RESEARCH;

EID: 84877120013     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.59     Document Type: Article

References (17)

1. Balducci C, Forloni G. APP transgenic mice: their use and limitations. Neuromolecular Med. 13 (2), 117 – 137 (2011).
2. Pifferi F, Rahman A, Languille S et al. Effects of dietary resveratrol on the sleep–wake cycle in the non-human primate gray mouse lemur (Microcebus murinus). Chronobiol. Int. 29 (3), 261 – 270 (2012).
3. Languille S, Blanc S, Blin O et al. The grey mouse lemur: a non-human primate model for ageing studies. Ageing Res. Rev. 11 (1), 150 – 162 (2012).
4. Baastrup C, Maersk-Moller CC, Nyengaard JR, Jensen TS, Finnerup NB. Spinal-, brainstem- and cerebrally mediated responses at- and below-level of a spinal cord contusion in rats: evaluation of pain-like behavior. Pain 151 (3), 670 – 679 (2010).
5. Baastrup C, Jensen TS, Finnerup NB. Coexisting mechanical hypersensitivity and anxiety in a rat model of spinal cord injury and the effect of pregabalin, morphine, and midazolam treatment. Scandinavian Journal of Pain 2 (3), 139 – 145 (2011).
6. Andrews N, Legg E, Lisak D et al. Spontaneous burrowing behaviour in the rat is reduced by Cipheral nerve injury or inflammation associated pain. Eur. J. Pain 16 (4), 485 – 495 (2012).
7. Ravassard P, Hazhouz Y, Pechberty S et al. A genetically engineered human pancreatic ß cell line exhibiting glucose-inducible insulin secretion. J. Clin. Invest. 121 (9), 3589 – 3597 (2011).
8. Obiol-Pardo C, Gomis-Tena J, Sanz F, Saiz J, Pastor M. A multiscale simulation system for the prediction of drug-induced cardiotoxicity. J. Chem. Inf. Model. 51 (2), 483 – 492 (2011).
9. Taboureau O, Jørgensen FS. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. Comb. Chem. High Throughput Screen. 14 (5), 375 – 387 (2011).
10. Matheis K, Laurie D, Andriamandroso C et al. A generic operational strategy to qualify translational safety biomarkers. Drug Discov. Today 16 (13–14), 600 – 608 (2011).
11. Dieterle F, Schuppe-Koistinen I, Prats N et al. The European IMI SAFE-T Consortium: qualification of translational safety biomarkers. Toxicol Lett. 189 (Suppl. 1), S157 (2009).
12. Taboureau O, Nielsen SK, Audouze K et al. ChemProt: a disease chemical biology database. Nucleic Acids Res. 39 (Suppl. 1), D367 – D372 (2011).
13. Bauer-Mehren A, Rautschka M, Sanz F, Furlong LI. DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks. Bioinformatics 26 (22), 2924 – 2926 (2010).
14. Garcia-Serna R, Mestres J. Anticipating drug side effects by comparative pharmacology. Expert Opin. Drug Metab. Toxicol. 6 (10), 1253 – 1263 (2010).
15. Briggs K, Cases M, Heard DJ et al. Inroads to predict in vivo toxicology – an introduction to the eTOX project. Int. J. Mol. Sci. 13 (3), 3820 – 3846 (2012).
16. Audouze K, Grandjean P. Application of computational systems biology to explore environmental toxicity hazards. Environ. Health Perspect. 119 (12), 1754 – 1759 (2011).
17. Bel EH, Sousa A, Fleming L et al. Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 66 (10), 910 – 917 (2011).